Pressemitteilung BoxID: 780858 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Ansprechpartner
  • Fabian Franke
  • +49 (30) 75019-134

Outlook for financial year 2016: aap aims for more than 20% trauma sales growth

(PresseBox) (Berlin, ) .

- Sales forecast for FY/2016 between EUR 30 million and EUR 34 million
- Sales organisation expanded and stronger focus on established markets
- Dynamic sales development expected from second half of the year
- Cost reduction planned in all divisions except sales 

aap Implantate AG (XETRA: AAQ.DE) aims to return to the growth track in financial year 2016. In this context in particular the trauma business shall serve as the growth driver. The Management Board anticipates trauma sales growth of 20% to 25% this year. The company's growth strategy is focused especially on established markets as the U.S., the DACH (Germany, Austria, Switzerland) region and other European countries. At the same time sales development in the BRICS and SMIT countries shall be stabilised.

In response to the business development in recent quarters aap significantly expanded its sales organisation. The sales team was strengthened with several executives with extensive experience and proven track records in the industry based on many years of service with renowned international medical technology companies.

Thanks to the substantial extension of the LOQTEQ® portfolio in financial year 2015 aap can now provide with an indication coverage of more than 90% for the treatment of big bone fractures. As a result the product family's attractiveness further increases, both for established markets and for hospital and purchasing groups as well as tendering procedures.

Based on the measures initiated and against the background of current global market developments the Management Board expects sales of EUR 30 million to EUR 34 million and an EBITDA of EUR 0.0 million to EUR 1.0 million for financial year 2016.

For the first quarter of 2016 the Management Board anticipates sales of EUR 4.5 million to EUR 6.0 million and an EBITDA of EUR -2.0 million to EUR -1.0 million. The background of this forecast is on the one hand a quarterly fluctuation in the biomaterials business primarily due to the ordering behaviour of the major customers for bone cements and mixing systems. On the other hand the Management Board expects that the sales measures initiated in the trauma business will become effective from the second half of 2016 and should then be reflected in a perceptibly more dynamic sales development. In this regard, it should be mentioned that the development of sales and earnings figures should be evaluated as an overall economic review on an annual basis rather than on a quarterly basis.

Management Agenda 2016

aap's Management Board has specified its targets for the current financial year as Management Agenda in four strategic and operational action areas.

Management Agenda Targets for 2016

A key element of the corporate strategy is the development of innovative and IP protected technologies and products, which build the basis for continuous value creation. aap's patented antibacterial silver coating technology addresses on the one hand a problem in surgery which hasn't yet been resolved adequately (infection risk when using metal implants) and has on the other hand a high value creation potential due to its wide range of applications. The superior target the Management Board continues to pursue within its strategy is to transform aap into a focused trauma company.

In the course of its future financial communication aap will report on sales developments in the trauma business (LOQTEQ®, standard trauma and trauma complementary biomaterials) and the biomaterials business (Bone cements and corresponding accessories as well as biomaterials).

aap plans to publish its consolidated annual financial report 2015 on 30 March 2016.

aap Implantate AG